Keyphrases
Kidney
100%
Kidney Disease Progression
100%
Albumin-to-creatinine Ratio
100%
Empa
100%
Empagliflozin
100%
Estimated Glomerular Filtration Rate
90%
Albuminuria
30%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
30%
Relative Difference
20%
Diabetes Status
20%
Cardiovascular Mortality
10%
Chronic Kidney Disease
10%
Japan
10%
China
10%
Placebo
10%
Italy
10%
Phase II Trial
10%
Progression Rate
10%
Rate of Change
10%
Intention-to-treat
10%
Canada
10%
Specific Types
10%
Relative Benefit
10%
Once-daily
10%
Germany
10%
Malaysia
10%
Cardiovascular Morbidity
10%
Absolute Difference
10%
Eli Lilly
10%
Kidney Outcomes
10%
Absolute Benefit
10%
Estimated Glomerular Filtration Rate Slope
10%
Shared Parameter Model
10%
Medicine and Dentistry
Albumin
100%
Creatinine
100%
Chronic Kidney Disease
100%
Glomerular Filtration Rate
100%
Empagliflozin
100%
Urinary System
100%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
40%
Albuminuria
30%
Cotransporter
30%
Diabetes
20%
Nephropathy
10%
Cardiovascular System
10%
Intention-to-Treat Analysis
10%
Placebo
10%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Creatinine
100%
Empagliflozin
100%
Albumin
100%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
40%
Albuminuria
30%
Cotransporter
30%
Placebo
10%
Kidney Disease
10%
Disease Exacerbation
10%